Recombinant sendai virus vector for introducing exogenous...

Details Recombinant sendai virus vector for introducing exogenous... Recombinant sendai virus vector for introducing exogenous...

2000-11-02

2008-01-01

Woitach, Joseph (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

C514S04400A, C435S325000, C435S320100

Reexamination Certificate

active

07314614

ABSTRACT:
Provided are a recombinant Sendai virus vector for introducing exogenous genes to airway epithelia and a method for introducing exogenous genes using the vector. The recombinant Sendai virus vector enables efficient gene transfer to native mucus-layered airway epithelial cells by briefly contacting the vector with the cells. Furthermore, the vector can introduce genes to not only apical surfaces but also submucosal glands where CFTR primarily expresses. The vector can thus be used for gene therapy of CF, a CFTR-deficient disease.

REFERENCES:
patent: 5670488 (1997-09-01), Gregory et al.
patent: 5824655 (1998-10-01), Border
patent: 5958893 (1999-09-01), Welsh et al.
patent: 6645760 (2003-11-01), Nagai et al.
patent: 6723532 (2004-04-01), Nagai et al.
patent: 6746860 (2004-06-01), Tokusumi et al.
patent: 6828138 (2004-12-01), Nagai et al.
patent: 2002/0002143 (2002-01-01), Kano et al.
patent: 2002/0098576 (2002-07-01), Nagai et al.
patent: 2002/0100066 (2002-07-01), Nagai et al.
patent: 2003/0166252 (2003-09-01), Kitazato et al.
patent: 2003/0170210 (2003-09-01), Masaki et al.
patent: 2003/0170266 (2003-09-01), Kitazato et al.
patent: 2003/0170897 (2003-09-01), Imai et al.
patent: 2003/0203489 (2003-10-01), Yonemitsu et al.
patent: 2004/0005296 (2004-01-01), Yonemitsu et al.
patent: 2004/0053877 (2004-03-01), Fukumura et al.
patent: 2004/0101965 (2004-05-01), Griesenbach et al.
patent: 2004/0121308 (2004-06-01), Nagai et al.
patent: 2006/0104950 (2006-05-01), Okano et al.
patent: 2007/0105208 (2007-05-01), You et al.
patent: 0 863 202 (1998-09-01), None
patent: 0 864 645 (1998-09-01), None
Deonarain (1998) Exp. Opin. Ther. Pat., 8(1): 53-69.
Gorecki (2001) Exp. Opin. Emerging Drugs, 6(2): 187-98.
Verma, et al. (1997) Nature, 389: 239-42.
Eck, et al. (1996) Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill, New York, NY., pp. 77-101.
Lamb, et al. (2001) Fundamental Virology, 4th Ed., Lippincott, Williams & Wilkins, New York, NY., p. 691.
Jenkins, et al. (2003) Monaldi Arch. Chest Dis., 53: 17-24.
Griesenbach, et al. (2003) Curr. Opin. Molec. Therap., 5(5) 489-94.
Dzau, et al. (1996) Proc. Natl. Acad. Sci., USA, 93: 11421-25.
Tashiro, et al. (1997) Frontiers in Bioscience 2: d588-91, internet publication, pp. 1-8.
Kato, et al. (1997) J. Virol., 71(10): 7266-72.
Hasan et al., “Creation of an Infectious Recombinant Sendai Virus Expressing the Firefly Luciferase Gene from the 3′ Proximal First Locus,”Journal of General Virology78:2813-2820 (1997).
Saeki et al., “Development and Characterization of Cationic Liposomes Conjugated with HVJ (Sendai Virus): Reciprocal Effect of Cationic Lipid for in vitro and in vivo Gene Transfer,”Human Gene Therapy8:2133-2141 (1997).
Sakai et al., “Accommodation of Foreign Genes into the Sendai Virus Genome: Sizes of Inserted Genes and Viral Replication,”FEBS Letters456:221-226 (1999).
Yonemitsu et al., “HVJ (Sendai Virus)-Cationic Liposomes: A Novel and Potentially Effective Liposome-Mediated Technique for Gene Transfer to the Airway Epithelium,”Gene Therapy4:631-638 (1997).
Yonemitsu et al., “Efficient Gene Transfer to Airway Epithelium Using Recombinant Sendai Virus,”Nature Biotechnology18:970-973 (2000).
McMorran et al., “G551D CF Mice Display an Abnormal Host Response and Have Impaired Clearance ofPseudomonasLung Disease,” Am. J. Physiol. Lung Cell Mol. Physiol. 281:L740-L747, (2001).
Cannon et al., “Pseudomonas aeruginosa-induced Apoptosis Is Defective in Respiratory Epithelial Cells Expressing Mutant Cystic Fibrosis Transmembrane Conductance Regulator,”Am. J. Respir. Cell Mol. Biol.29(2):188-197 (2003).
Delaney et al., “Cystic Fibrosis Mice Carrying the Missense Mutation G551D Replicate Human Genotype-Phenotype Correlations,”The EMBO Journal15(5):955-963 (1996).
Oceandy et al., “Gene Complementation of Airway Epithelium in the Cystic Fibrosis Mouse is Necessary and Sufficient to Correct the Pathogen Clearance and Inflammatory Abnormalities,”Human Molecular Genetics11(9):1059-1067 (2002).
Stonebraker et al., “Glycocalyx Restricts Adenoviral Vector Access to Apical Receptors Expressed on Respiratory Epithelium In Vitro and In Vivo: Role for Tethered Mucins as Barriers to Lumenal Infection,”Journal of Virology78(24):13755-13768 (2004).
Thomas et al., “G551D Cystic Fibrosis Mice Exhibit Abnormal Regulation of Inflammation In Lungs and Macrophages,”The Journal of Immunology164(7):3870-3877 (2000).
U.S. Appl. No. 10/543,734, filed Feb. 7, 2006, Tokusumi et al.
U.S. Appl. No. 10/562,408, filed Dec. 23, 2005, You et al.
Kato et al., “The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis,”EMBO J.16(3): 578-587, (1996).

Affiliated with

Also associated with

Rating

Recombinant sendai virus vector for introducing exogenous... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant sendai virus vector for introducing exogenous..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant sendai virus vector for introducing exogenous... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3964912